Form 4 for DCOY Decoy Therapeutics Inc.
Accepted 2025-11-20 00:00:00 ET · period of report 2025-11-20 · accession 0001615219-25-000177 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | 2025-11-20 | DCOY | Rosenblum Mark J | CFO, EVP Fin | P - Purchase | $0.8 | +20.0K | 20.2K | +11,299% | +$16.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | P | A | 20,000 | $0.8 | 20,177 | D | — | — | (F2) Includes 20 shares of unvested restricted stock granted on January 3, 2023. (F1) Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025. |